Clarithromycin Inhibits Progeny Virus Production from Human Influenza Virus-Infected Host Cells

Daisei Miyamoto; Sayaka Hasegawa; Nongluk Sriwilaijaroen; Sangchai Yingsakmongkon; Hiroaki Hiramatsu; Tadanobu Takahashi; Kazuya Hidari; Chao-Tan Guo; Yuichi Sakano; Takashi Suzuki; Yasuo Suzuki

doi:10.1248/bpb.31.217

Regular Articles

Clarithromycin Inhibits Progeny Virus Production from Human Influenza Virus-Infected Host Cells

Daisei Miyamoto, Sayaka Hasegawa, Nongluk Sriwilaijaroen, Sangchai Yingsakmongkon, Hiroaki Hiramatsu, Tadanobu Takahashi, Kazuya Hidari, Chao-Tan Guo, Yuichi Sakano, Takashi Suzuki, Yasuo Suzuki

Author information

Daisei Miyamoto
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Global COE Program for Innovation in Human Health Sciences, University of Shizuoka School of Pharmaceutical Sciences
Sayaka Hasegawa
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science
Global COE Program for Innovation in Human Health Sciences, University of Shizuoka School of Pharmaceutical Sciences
Nongluk Sriwilaijaroen
Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University
Graduate Studies, Faculty of Medicine, Thammasat University (Rangsit Campus)
Sangchai Yingsakmongkon
Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University
Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University
Hiroaki Hiramatsu
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University
Tadanobu Takahashi
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Global COE Program for Innovation in Human Health Sciences, University of Shizuoka School of Pharmaceutical Sciences
Kazuya Hidari
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Global COE Program for Innovation in Human Health Sciences, University of Shizuoka School of Pharmaceutical Sciences
Chao-Tan Guo
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University
Zhejiang Academy of Medical Sciences
Yuichi Sakano
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science
The Japan Health Science Foundation
Takashi Suzuki
Department of Biochemistry, University of Shizuoka School of Pharmaceutical Science
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Global COE Program for Innovation in Human Health Sciences, University of Shizuoka School of Pharmaceutical Sciences
Yasuo Suzuki
Core Research for Evolutional Science and Technology (CREST, JST), University of Shizuoka School of Pharmaceutical Sciences
Global COE Program for Innovation in Human Health Sciences, University of Shizuoka School of Pharmaceutical Sciences
Department of Biomedical Sciences, College of Life and Health Sciences, Chubu University

Keywords: clarithromycin, influenza virus, anti-influenza drug

JOURNAL FREE ACCESS

2008 Volume 31 Issue 2 Pages 217-222

DOI https://doi.org/10.1248/bpb.31.217

Details

Abstract

In vitro effects of macrolide clarithromycin (CAM) on influenza A virus-infected cells were examined using plaque reduction assay by treating cells either before or after viral adsorption. The significant inhibitory effect on influenza virus infection was detected only when the cells were treated with CAM after viral adsorption. The predominant inhibitory effect was observed during 4—7th hour after viral adsorption using viral production assay. CAM did not exhibit inhibitory effects on influenza virus hemagglutination, membrane fusion and viral sialidase activities. These findings indicate that CAM acts on a middle to late stage of the viral replication cycle resulting in inhibition of progeny virus production from the infected cells.

Corresponding author

Register with J-STAGE for free!